(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Stoke Therapeutics (STOK) has an average rating of buy and price targets ranging from $32 to $83, according to analysts polled by Capital IQ. (MT Newswires...
(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...
Stoke Therapeutics (STOK) reported a Q4 net loss Thursday of $0.66 per diluted share, widening from a $0.42 loss a year earlier. Analysts polled by...
Stoke Therapeutics (STOK) has an average rating of Buy and price targets ranging from $41 to $83, according to analysts polled by Capital IQ. (MT Newswires...
Acadia Pharmaceuticals (ACAD) and Stoke Pharmaceuticals (STOK) said Monday they have formed a partnership to discover, develop and commercialize novel...
Stoke Therapeutics (STOK) said Friday that a phase 1/2a study of its STK-001 candidate to treat Dravet syndrome showed that 70.6% of patients saw a...
Stoke Therapeutics (STOK) has an average rating of outperform and price targets ranging from $34 to $83, according to analysts polled by Capital IQ. (MT...
Stoke Therapeutics (STOK) was up nearly 14% after JPMorgan upgraded the company to overweight from neutral. The investment firm's price target on the...